AAP News Vol. 15 No. 5 May 1999, p. 4
© 1999 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Llewellyn, S. T.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Academy seeks to intervene in drug lawsuit

Sherry Trust Llewellyn

As pediatric health practitioners, AAP members know better than anyone the frustration of prescribing drugs that have not been labeled for use in children. A recent federal law, the Food and Drug Administration Modernization Act (FDAMA), addresses this problem, but the law could be halted before it is ever fully implemented.

The generic drug industry has filed a lawsuit to stop the pediatric drug label rule of FDAMA in its tracks, but the Academy is fighting for the provision's survival.